CHICAGO -- A paradigm-changing clinical trial in prostate cancer showed that perioperative apalutamide (Erleada) and androgen ...

"The light goes out of their eyes in about 3 years. This is not what they signed up for." -- Clark Coler, MD, of Swedish ...

The problem is that regulatory incentives are fundamentally asymmetric. Approving a dangerous therapy generates headlines, ...

Critics of these alternative plans say the major issues occur when people use them as primary insurance and don't realize the ...

Donald Trump's physician says the president is in "excellent health" and is "fully fit" to serve as commander in chief after a medical exam Tuesday at Walter Reed National Military Medical Center that ...

The adjuvant treatment of RET fusion-positive non-small-cell lung cancer (NSCLC) following potentially curative surgery or radiotherapy has a new standard of care, researchers reported here. In a ...

CHICAGO -- A first-in-class bispecific antibody targeting PD-1 and VEGF combined with chemotherapy significantly improved overall survival (OS) in patients with advanced squamous non-small cell lung ...

CHICAGO -- Treatment with the CDK4/6 inhibitor abemaciclib (Verzenio) offered a dramatic survival uptick in a highly aggressive soft-tissue cancer that rarely responds to chemotherapy, according to ...

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) also discussed the need to target the long-simmering ...

CHICAGO -- Men with metastatic castration-sensitive prostate cancer (mCSPC) and DNA repair alterations had significantly longer progression-free survival (PFS) with a targeted drug plus an androgen ...

CHICAGO -- RASolute 302 trial results were hailed as a game-changing breakthrough in the treatment of pancreatic cancer. The phase III study showed that second-line daraxonrasib, an investigational ...

Legally, the Laikipia plan walks a dangerous constitutional tightrope. While the government possesses broad quarantine powers ...